WHO Drug Information Vol. 25, No. 2, 2011
WHO Drug Information Vol. 25, No. 2, 2011
WHO Drug Information Vol. 25, No. 2, 2011
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>WHO</strong> <strong>Drug</strong> <strong>Information</strong> <strong>Vol</strong>. <strong>25</strong>, <strong>No</strong>. 2, <strong>2011</strong> Proposed INN: List 1051227158-72-6Fused chain / chaine fusionnée / cadena fusionadaGRPFVEMYSE IPEIIHMTEG RELVIPCRVT SPNITVTLKK FPLDTLIPDG 50KRIIWDSRKG FIISNATYKE IGLLTCEATV NGHLYKTNYL THRQTNTIID 100VVLSPSHGIE LSVGEKLVLN CTARTELNVG IDFNWEYPSS KHQHKKLVNR 150DLKTQSGSEM KKFLSTLTID GVTRSDQGLY TCAASSGLMT KKNSTFVRVH 200EKPFVAFGSG MESLVEATVG ERVRIPAKYL GYPPPEIKWY KNGIPLESNH <strong>25</strong>0TIKAGHVLTI MEVSERDTGN YTVILTNPIS KEKQSHVVSL VVYVPPGPGD 300KTHTCPLCPA PELLGGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSHEDP 350EVKFNWYVDG VEVHNAKTKP REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC 400KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSRDELTKN QVSLTCLVKG 450FYPSDIAVEW ESNGQPENNY KATPPVLDSD GSFFLYSKLT VDKSRWQQGN 500VFSCSVMHEA LHNHYTQKSL SLSPGK 526Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-chain 27-76 121-182 340-400 446-50427'-76' 121'-182' 340'-400' 446'-504'Inter-chains 305-305' 308-308'N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación376, 376'crenezumabum #crenezumabcrénezumabcrenezumabimmunoglobulin G4-kappa, anti-[Homo sapiens amyloid beta (Abeta)peptides Aβ42 and Aβ40]], humanized monoclonal antibody;gamma4 heavy chain (1-438) [humanized VH (Homo sapiensIGHV3-23*04 (89.70%) -(IGHD)-IGHJ4*01 L123>T (107) [8.8.5](1-112) -Homo sapiens IGHG4*01 hinge S10>P (220) (113-438)],(126-219')-disulfide with kappa light chain (1'-219') [humanizedV-KAPPA (Homo sapiens IGKV2D-29*02 (86.00%) -IGKJ1*01)[11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; (218-218":221-221")-bisdisulfide dimerimmunomodulatorimmunoglobuline G4-kappa, anti-[Homo sapiens peptides bêtaamyloïdes(Abêta) Aβ42 et Aβ40]], anticorps monoclonal humanisé;chaîne lourde gamma4 (1-438) [VH humanisé (Homo sapiensIGHV3-23*04 (89.70%) -(IGHD)-IGHJ4*01 L123>T (107) [8.8.5](1-112) -Homo sapiens IGHG4*01 charnière S10>P (220) (113-438)], (126-219')-disulfure avec la chaîne légère kappa (1'-219')[V-KAPPA humanisé (Homo sapiens IGKV2D-29*02 (86.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')];dimère (218-218":221-221")-bisdisulfureimmunomodulateurinmunoglobulina G4-kappa, anti-[péptidos beta-amiloides (Abeta)Aβ42 y Aβ40 de Homo sapiens]], anticuerpo monoclonalhumanizado;cadena pesada gamma4 (1-438) [VH humanizada (Homo sapiensIGHV3-23*04 (89.70%) -(IGHD)-IGHJ4*01 L123>T (107) [8.8.5](1-112) -Homo sapiens IGHG4*01 bisagra S10>P (220) (113-438)],(126-219')-disulfuro con la cadena ligera kappa (1'-219')[V-KAPPA humanizada (Homo sapiens IGKV2D-29*02 (86.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')];dímero (218-218":221-221")-bisdisulfuroinmunomodulador163
Change language